Novartis is responding to COVID-19 with the safety of our associates and patients we serve as our main concern. We continue to contribute to global research efforts, support local communities and ensure stable supply and price of essential medicines. This US information center provides updates, guidance and other resources.

novartis development specialist 1 image_0

Information update about the Novartis CAN-COVID trial

The CAN-COVID clinical trial has been one of the ways Novartis is drawing on its global resources and scientific expertise in response to the COVID-19 pandemic.

Novartis scientists working in a lab

Life Science Companies and the Bill & Melinda Gates Foundation: Joint Communique

Commitments to expanded global access for COVID-19 diagnostics, therapeutics, and vaccines.

Woman working from home on her computer. credit : Coursera

Novartis US response to COVID-19

Since the first reports of the COVID-19 outbreak globally and in the US, our primary concern at Novartis has and continues to be the health and safety of our associates and patients.

Man in front of computer monitor

Novartis US COVID-19 Initiatives

We recognize the profound impact that COVID-19 has had on patients and physicians in the US, and have worked to create solutions in a time of uncertainty and change.

coronavirus covid 19 hero image_0

Coronavirus disease (COVID-19) Global updates

As Novartis continues to closely monitor the coronavirus situation, our primary concern is the health and safety of our associates and patients globally.

Illustration: Coronavirus (Centers for Disease Control and Prevention)

Novartis COVID-19 Global Information Center

Novartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources.